Imagine a world where tuberculosis (TB) treatment is drastically shorter, simpler, and more effective. Sounds too good to be true? Well, groundbreaking research suggests we might be closer than ever. A new drug, sorfequiline, has shown remarkable promise in early trials, potentially revolutionizing how we tackle this ancient disease. But here's where it gets controversial: could this drug not only shorten treatment but also challenge the way we approach TB diagnosis and therapy altogether?
An international team of researchers recently unveiled exciting data from a Phase 2 trial of sorfequiline (TBAJ-876), a second-generation diarylquinoline antibiotic. Presented at the Union World Conference on Lung Health in Copenhagen, the interim results reveal that sorfequiline outperformed existing treatments in combating drug-susceptible TB within just 8 weeks, all while maintaining a favorable safety profile. This marks the first human trial of the drug, developed by TB Alliance since 2014, and the findings are compelling enough to greenlight a Phase 3 trial.
Dr. Maria Beumont, a trial investigator with TB Alliance, expressed optimism about the drug's potential to shorten treatment durations for both drug-susceptible and drug-resistant TB—a disease that affected an estimated 10.7 million people in 2024. "We envision a future with significantly shorter treatment times, and this is the crucial first step toward that goal," she told CIDRAP News.
The randomized controlled trial, conducted across South Africa, the Philippines, Georgia, Tanzania, and Uganda, enrolled 309 participants with newly diagnosed drug-susceptible TB. Participants were divided into five treatment groups: the standard HRZE regimen (isoniazid, rifampin, pyrazinamide, ethambutol), the BPaL regimen (bedaquiline, pretomanid, linezolid), and three variations of the SPaL regimen (sorfequiline, pretomanid, linezolid) with different sorfequiline doses (25, 50, and 100 mg). The primary goal? Measuring sputum conversion—a key indicator of TB treatment efficacy—at week 8.
While HRZE remains the WHO-recommended first-line treatment for drug-susceptible TB, requiring 6 months of multiple daily pills, and BPaL is the go-to for drug-resistant TB with a similar duration, sorfequiline could be a game-changer. Dr. Beumont highlighted that sorfequiline, belonging to the same antibiotic class as bedaquiline, may offer superior robustness and tolerability. "It’s not just about treating existing strains," she noted. "Sorfequiline shows potential against emerging TB strains resistant to bedaquiline."
At week 8, 59% of participants on SPaL with 100 mg of sorfequiline achieved sputum conversion, compared to 45% in both the HRZE and BPaL groups. These results not only demonstrate greater efficacy but also hint at the possibility of shorter treatment times. "The faster reduction in Mycobacterium burden is a strong indicator of both efficacy and the potential to condense treatment," Dr. Beumont explained.
Safety-wise, SPaL matched HRZE, and participants appreciated the simplicity of just three daily pills. "The treatment was amazing—shorter and easier than I expected," shared Thuto Pulane, a trial participant, in a TB Alliance press release.
Looking ahead, TB Alliance plans to launch a Phase 3 trial testing SPaL in both drug-susceptible and drug-resistant TB patients. If successful, the treatment duration could shrink to just 4 months: one month of oral medication followed by a long-lasting injectable form providing three months of coverage. "For patients, this would mean only one month of pills," Dr. Beumont emphasized.
Even more revolutionary is the possibility of SPaL becoming a universal first-line treatment, eliminating the need to wait for test results to determine the TB strain. In low-resource settings, where diagnostic delays are common, this could be a lifesaver.
Dr. KJ Seung, a TB researcher unaffiliated with the trial, finds the interim data encouraging. "After years of limited progress in TB drug development, it’s refreshing to see a robust pipeline of new treatments," he said. But he cautions that we await the full results before drawing definitive conclusions.
And this is the part most people miss: If sorfequiline lives up to its promise, it could not only transform TB treatment but also spark debates about the future of diagnostic protocols and resource allocation in global health. Could this be the beginning of the end for lengthy, cumbersome TB treatments? Or are we setting unrealistic expectations? What do you think? Share your thoughts in the comments below—let’s keep the conversation going!
